The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://prestonnnvy155265.wikicorrespondence.com/6038408/glp_3_retatrutide_a_comparative_analysis